Tecentriq patent expiry?

Tecentriq (pembrolizumab) – Patent Landscape & Expiry Dates (U.S. & Global)

Bottom line: The key composition‑of‑matter patents for Tecentriq (pembrolizumab) are still active in the United States, with the earliest expiring in 2024. Most of the method‑of‑use patents will remain in force through the 2020s.

Global Patents & Expiry

Key point: In most major markets, the core patents are still in force, with many expiring between 2024‑2027. In some jurisdictions (e.g., certain Latin American countries), patent terms may be shorter due to different filing‑to‑expiry calculations, but still usually beyond 2020.

Biosimilars & Generics

Bottom line: No commercial biosimilar or generic version of Tecentriq is currently available. The first biosimilar is expected to enter the market by the end of the 2020s, but full market penetration will likely take several years as physicians and payors assess interchangeability and cost‑effectiveness.

Practical Take‑aways

1. Patent Protection – In the U.S. and most global markets, Tecentriq’s core patents remain active through at least 2026‑2030.
2. First Biosimilar – A biosimilar is likely to become available in the U.S. around 2029‑2030, after the U.S. Patent Term Extension (if any) ends.
3. Pricing & Access – Because patents are still in force, pricing and reimbursement will continue to reflect the brand’s market positioning. Once biosimilars enter, a price drop is expected, but uptake will depend on insurance coverage and physician preference.
4. Regulatory Updates – Keep an eye on the FDA’s Biosimilars Advisory Committee and EMA’s Committee for Advanced Therapies for timelines on approval decisions.

Quick FAQ

Bottom line for clinicians & payors: The Tecentriq (pembrolizumab) patent portfolio remains strong through the mid‑2020s, delaying biosimilar entry. Monitoring upcoming biosimilar approvals and potential patent term extensions will be key to anticipating market shifts and planning formulary strategies.